Podium to Practice: Chicago 2026 – LUNG: LIBRETTO-432 & AcceleRET-Lung study

Podium to Practice: Chicago 2026 – LUNG: LIBRETTO-432 & AcceleRET-Lung study

Podium to Practice: Chicago 2026

Studies / Trials Discussed

LBA3 – Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.

8504 – Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.

Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Paul Wheatley-Price

Dr. Rosalyn Juergens

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

LBA3 – Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial. 8504 – Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
Tagged